Sep 13: Drug maker Zydus Cadila on Thursday said that it has received the final approval from the USFDA to market its Risedronate Sodium Delayed-Release Tablets (US RLD — ATELVIA delayed-release tablets), 35 mg.
According to the company, Risedronate is a medicine of bisphosphonate group that alters bone formation and breakdown in the body. This can slow bone loss and may help prevent bone fractures. This medicine is used to treat osteoporosis in women, caused by menopause, it said.
The product will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad, the company added.
Based in Ahmedabad, the Pankaj R Patel promoted Zydus Cadila Group is a research driven drug maker that discovers, develops, manufactures and markets a broad range of healthcare therapies.
The group now has 218 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04